$177 Million is the total value of Stonepine Capital Management, LLC's 21 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | Aegerion Pharmaceuticals, Inc.note | $13,280,000 | -23.0% | 16,600,000 | -31.4% | 7.48% | -27.1% | |
| ALR | Sell | Alere Inc. | $10,926,000 | -22.1% | 275,000 | -23.6% | 6.16% | -26.3% |
| CRME | Sell | Cardiome Pharma Corp | $8,299,000 | -4.8% | 2,757,260 | -12.7% | 4.68% | -9.9% |
| ENTA | Sell | Enanta Pharmaceuticals | $5,701,000 | -26.6% | 185,099 | -20.2% | 3.21% | -30.6% |
| VCYT | Sell | Veracyte, Inc. | $5,308,000 | -29.3% | 578,200 | -40.4% | 2.99% | -33.1% |
| ALIM | Sell | Alimera Sciences, Inc | $3,607,000 | -27.6% | 2,576,273 | -44.2% | 2.03% | -31.5% |
| TRIB | Sell | Trinity Biotech PLC - SPON ADRspons adr | $2,097,000 | -30.5% | 351,917 | -19.3% | 1.18% | -34.3% |
| CTIC | Exit | CTI Biopharma Corp | $0 | – | -2,617,136 | -100.0% | -0.64% | – |
| JNP | Exit | Juniper Pharmaceuticals, Inc. | $0 | – | -228,392 | -100.0% | -0.76% | – |
| CUTR | Exit | Cutera, Inc. | $0 | – | -120,429 | -100.0% | -1.24% | – |
| MNKKQ | Exit | Mallinckrodt PLC | $0 | – | -43,629 | -100.0% | -1.30% | – |
| FLML | Exit | Flamel Technologies - SP ADRspons adr | $0 | – | -326,087 | -100.0% | -2.02% | – |
| SCMP | Exit | Sucampo Pharmaceuticals - CL A | $0 | – | -284,002 | -100.0% | -2.29% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.